Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III clinical trial of soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU)

Next Previous
Trial Profile

A Phase II/III clinical trial of soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU)

Status: Planning
Phase of Trial: Phase II/III

Latest Information Update: 02 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Soficitinib (Primary)
  • Indications Urticaria
  • Focus Therapeutic Use

Most Recent Events

  • 02 Jan 2026 New trial record
  • 18 Dec 2025 According to InnoCare Pharma media release, company announced the approval of the Investigational New Drug (IND) by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to conduct a Phase II/III clinical trial of novel TYK2 inhibitor soficitinib (ICP-332) for the treatment of chronic spontaneous urticaria (CSU).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top